• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Alefacept may be effective therapy in newly diagnosed type 1 diabetics

bys25qthea
September 28, 2013
in Chronic Disease, Endocrinology
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. In patients with newly diagnosed type 1 diabetes, treatment with alefacept significantly increased 4 hour C-peptide release and significantly reduced both insulin use and the rate of hypoglycemic events compared to placebo at 12 month follow-up. 

2. Alefacept led to decreases in CD4 and CD8 memory T cells with a resultant increase in the ratio of regulatory T cells to memory T cells. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: T1DAL is a randomized controlled trial examining alefacept’s ability to preserve pancreatic beta cell function in new-onset type 1 diabetes. Previously used to treat psoriasis, alefacept binds to CD2, a cell surface protein that is highly expressed on memory T cells. The primary endpoint was change from baseline in 2 hour (h) C-peptide levels, determined by assessment of the area under the curve (AUC), at 12 month follow-up. Differences between alefacept and placebo were not significant. However, alefacept significantly increased mean 4 h C-peptide AUC at 12 months and significantly reduced both insulin use and the incidence of hypoglycemia. No significant differences in rates of adverse effects were noted between the treatment and control groups. Flow cytometric analysis revealed decreases in effector and central memory T cells, but not T regulatory cells (Tregs).

While several trials of immunosuppressants have shown evidence of beta cell preservation, alefacept is the first drug to suppress effector and central memory T cells while sparing Tregs. An increased ratio of Tregs to memory T cells might conceivably induce immunologic tolerance. Encouragingly, alefacept has been shown to induce long-term remission in some psoriasis patients. It is unclear how long benefits will persist after alefacept administration. Larger studies with longer follow-up will be needed to confirm drug efficacy and better characterize adverse effects of this immunosuppressant.

Click to read the study in The Lancet

RELATED REPORTS

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

Click to read an accompanying comment in The Lancet

Relevant Reading: Type 1 diabetes: translating mechanistic observations into effective clinical outcomes

Study Author, Professor Rigby, Riley Hospital for Children at Indiana University, USA, talks to 2 Minute Medicine:,

“Alefacept is the first targeted biological drug assessed in patients with new-onset type 1 diabetes that significantly depleted the T cells which attack the pancreas in type 1 diabetes, while preserving other immune cells which are important for pancreatic function.  Although the primary endpoint was not met, several key secondary endpoints were significantly different between treatment groups, suggesting that alefacept might preserve pancreas cell function during the first 12 months after diagnosis. Targeting memory T cells might be a useful strategy in type 1 diabetes, but longer follow-up is required to confirm the preliminary signal of efficacy observed at 12 months in the T1DAL trial.”

In-Depth [double-blind randomized controlled trial]: This phase 2 trial randomized 49 patients with type 1 diabetes to either alefacept or placebo. Patients were enrolled within 100 days of diagnosis. Those in the alefacept group received two 12-week courses of weekly intramuscular alefacept with an intervening 12-week pause.  The primary endpoint was change from baseline in mean 2 h C-peptide secretion, as measured by AUC, following a mixed meal tolerance test administered at 12 months. Secondary outcomes included change in mean 4 h C-peptide AUC at 12 months, insulin use at 12 months, hypoglycemic events, and HbA1c concentration at 12 months.

At 12 months, the alefacept group had a mean increase in 2 h C-peptide AUC (0.015 nmol/L, 95% CI -0.080 – 0.110) whereas the placebo group had a mean decrease of 0.115 nmol/L (95% CI -0.278 – 0.047).  This difference was not significant. However, the increase in mean 4 h C-peptide AUC was significantly greater in the alefacept group (increase of 0.015 nmol/L vs. decrease of 0.156 nmol/L in control group, p=0.019). Compared to placebo, alefacept resulted in significantly less daily insulin use at 12 months (0.36 units/kg vs. 48 units/kg, p=0.02) and fewer hypoglycemic events (10.9 events/person/year vs. 17.3 events/person/year, p<0.0001). Mean HbA1c concentration and side effect frequency and severity did not differ between groups. Five patients in the alefacept group had doses held temporarily when their CD4 counts dropped lower than 250 cells/mL. Flow cytometry revealed reductions of 25-60% in CD4 central memory T cells (p<0.001), CD4 effector memory T cells (p=0.002), and CD8 central memory T cells (p=0.003) at all timepoints examined. However, the frequency of Tregs was unchanged.

By Hayley Walker and Mimmie Kwong 

More from this author: Key patient characteristics predict outcomes in children with cardiomyopathy, Remote ischemic preconditioning reduced myocardial injury in CABG patients

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: alefaceptdiabetesglucose
Previous Post

Radial artery harvest comparable to saphenous vein harvest for cardiac bypass

Next Post

Secondary mastoid obliteration improves quality of life for patients with chronic otitis media

RelatedReports

Classics Series, Landmark Trials in Medicine
Emergency Classics

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

May 4, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Chronic Disease

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

April 29, 2022
Filtered-sunlight may effectively treat neonatal jaundice in resource-poor settings
Cardiology

Light exposure during sleep may alter glucose metabolism and impair cardiometabolic function

April 19, 2022
Next Post
Secondary mastoid obliteration improves quality of life for patients with chronic otitis media

Secondary mastoid obliteration improves quality of life for patients with chronic otitis media

Improved survival with bufulfan-cyclophosphamide combination vs total body irradiation

Improved survival with bufulfan-cyclophosphamide combination vs total body irradiation

The CRASH-2 trial: Tranexamic acid in trauma patients [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.